ObjectiveThis post-hoc pooled analysis evaluated categorical change in functional
impairment in patients with major depressive disorder (MDD) treated with desvenlafaxine …

Specific serotonin reuptake inhibitors (SSRIs) are considered as first-line treatment in major
depressive disorder (MDD). There is evidence that venlafaxine may be more effective than …

The estimated rate of treatment-resistant major depressive disorder (TRD) remains higher
than 30%, even after the discovery of multiple classes of antidepressants in the last 7 …

This issue of CNS Spectrums hosts an article that discusses the use of long-term and high-
dose desvenlafaxine for treating major depressive disorder (MDD) and a meta-analytic …

Background: Approximately half of patients who are prescribed selective serotonin reuptake
inhibitors (SSRIs) either do not respond to treatment or do not experience a sustained …

Background: This series of experiments was conducted to describe the metabolic profile of
the serotoninnorepinephrine reuptake inhibitor desvenlafaxine (administered as …

Background Diminished quality of life (QOL) is associated with major depressive disorder
(MDD). Methods QOL was assessed in a post-hoc analysis of a double-blind, placebo …

This study compared the stabilized duloxetine dose through approximately 12 weeks of
treatment in patients initiating duloxetine therapy with that in patients switching to duloxetine …

The aim of this study was to assess antidepressant efficacy and safety of venlafaxine
extended release in Japanese patients with major depressive disorder (MDD). We carried …

Background: Major depressive disorder is characterized by the presence of at least five of
nine specific symptoms that contribute to clinically significant functional impairment. This …